Global Immuno-Oncology Diagnostics Market Report 2023-2028: Diagnostic Companies and Instrumentation Suppliers are Jockeying for Position in a New Approach to Conquering Cancer

Rhea-AI Summary

The Global Immuno-Oncology Diagnostics Market Report 2023-2028 has been released by ResearchAndMarkets.com. The report highlights a rapidly growing segment within diagnostics, fueled by advancements in histology, genomics, and liquid biopsy. This area seeks to enhance cancer therapies by utilizing the body's immune defenses, making biomarkers crucial for effective treatment selection. The market is characterized by intense competition among pharmaceutical and diagnostic companies. Key topics include market definitions, technology trends, and critical developments impacting the industry, suggesting significant growth potential in immuno-oncology diagnostics.

Positive

• Rapid growth in the immuno-oncology diagnostics market is noted, driven by advancements in technology.
• Strong focus on utilizing immune system strategies in cancer therapy suggests increasing market relevance.
• Collaboration among diagnostic and pharmaceutical companies indicates a dynamic market environment.

Negative

• The pace of technology development may outstrip market readiness, posing potential challenges.
• Complexity in diagnostic roles and clinical trial protocols could limit market growth.

DUBLIN, Jan. 19, 2023 /PRNewswire/ -- The "Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates" report has been added to  ResearchAndMarkets.com's offering.

Diagnostics, companion diagnostics, is driving the success of Immuno-oncology Therapeutics. An entire new segment of the diagnostics industry is being created and its not a small segment either. It promises to grow dramatically.

Histology, genomics and liquid biopsy are converging. A complicated network of pharmaceutical companies, diagnostic companies and instrumentation suppliers are jockeying for position in a new approach to conquering cancer. The approach seems to be working and showing great promise.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success but diagnostics, especially biomarkers, are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines?

Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size in this new expanded and comprehensive report.

Key Topics Covered:

1 Market Guides
1.1 Situation Analysis & Impact of COVID-19 Pandemic
1.2 Guide for Executives and Marketing Staff
1.3 Guide for Investment Analysts and Management Consultants

2 Introduction and Market Definition
2.1 What are Immuno-Oncology Diagnostics?
2.2 Immuno-oncology - the looming cure
2.2.1 Immuno-oncology Diagnostics Takes a Leading Role
2.3 Market Definition
2.3.1 Market Size
2.3.2 Currency
2.3.3 Years
2.4 Methodology
2.4.1 Authors
2.4.2 Sources
2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics

3 Immunotherapy - Guide to Immune Technologies
3.1 The Immune System
3.1.1 Innate immune system
3.1.1.1 Surface barriers
3.1.1.2 Inflammation
3.1.1.3 Complement system
3.1.1.4 Cellular barriers
3.1.1.5 Natural killer cells
3.1.2 Adaptive immune system
3.1.2.1 Lymphocytes
3.1.2.2 Killer T cells
3.1.2.3 Helper T cells
3.1.2.4 Gamma delta T cells
3.1.2.5 B lymphocytes and antibodies
3.1.3 Tumor immunology - the immune surveillance system
3.2 Immuno Oncology Diagnostics
3.2.1 Checkpoint Assays
3.2.1.1 Outlook for Checkpoint Assays
3.2.2 Cytokine Assays
3.2.3 Genomic Germline
3.2.4 Genomic Tumour
3.2.5 Tumor Microenviroment
3.2.6 Other Diagnostics

4 Industry Overview
4.1 Players in a Dynamic Market
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Genomic Instrumentation Supplier
4.1.4 Cell Separation and Viewing Instrumentation Supplier
4.1.5 Pharmaceutical/Reagent Supplier
4.1.6 Independent Testing Lab
4.1.7 Public National/regional lab
4.1.8 Hospital lab
4.1.9 Physician Lab
4.1.10 Audit Body
4.1.11 Certification Body

5 Market Trends
5.1 Factors Driving Growth
5.1.1 Outcome potential
5.1.2 Companion Diagnostics
5.1.3 Funding
5.1.4 Technology Environment
5.1.5 Target Solutions
5.2 Factors Limiting Growth
5.2.1 Complex Role of Diagnostics
5.2.2 Clinical Trials Role
5.2.3 Protocols
5.3 Diagnostic Technology Development
5.3.1 Combinations - Issues and Complexity
5.3.2 Shifting Role of Diagnostics
5.3.3 Multiplexing and Foundation One
5.3.4 The Disruption Dynamic
5.3.5 The Race for Biomarkers
5.3.6 The Next Five Years

6 Cancer Immuno-Oncology Diagnostics Recent Developments
6.1 Recent Developments - Importance and How to Use This Section
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 Lucence Liquid Biopsy Test Tracks Immune Treatment ctDNA Changes
6.3 Qiagen, OncXerna Close Companion Dx Development Deal
6.4 Natera Test to Guide Therapy for Bladder Cancer
6.5 Veracyte Halio Acquisition to Boost Immuno-oncology Activity
6.6 Freenome Eyes New Dx Possibilities
6.7 Oncocyte Data has Potential as Immunotherapy Response Predictor
6.8 OncoDNA use HalioDx to Expand into North America
6.9 Adaptive Biotechnologies, Q2 Solutions Agreement for ImmunoSeq Assay .
6.10 Qiagen Expands Immuno-Oncology Portfolio
6.11 Immune Profiling System Redirected to Fight COVID-19
6.12 IncellDx Awarded PD-L1 Detection Patent
6.13 FDA Approves CDx for Trastuzumab
6.14 Promega Nabs CE Mark for Microsatellite Instability IVD
6.15 ArcherDx partners with AstraZeneca for Immuno-Oncology
6.16 Germline Results Guides Precision Therapy
6.17 Agilent PD-L1 Assay Gets FDA Approval
6.18 Bayer, OrigiMed Form Companion Diagnostic Development Alliance
6.19 Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy
6.20 SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures
6.21 Biocare Medical Launches 7 Novel IVD Antibodies
6.22 Oncocyte to Acquire Insight Genetics for $12M
6.23 Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
6.24 Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
6.25 Generex to Merge with NuGenerex Immuno-Oncology
6.26 Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop Companion Diagnostics for Cancer Therapies
6.27 Hematogenix Launches FDA Approved Immuno-oncology Test for Triple Negative Breast Cancer
6.28 Icon Acquires MolecularMD

7 Profiles of Key Immuno-oncology Companies
7.1 10x Genomics, Inc.
7.2 Abbott Diagnostics
7.3 AccuraGen Inc.
7.4 Adaptive Biotechnologies
7.5 Aethlon Medical
7.6 Agena Bioscience, Inc
7.7 Agilent/Dako
7.8 Anchor Dx
7.9 ANGLE plc
7.10 ApoCell, Inc.
7.11 ARUP Laboratories
7.12 Asuragen
7.13 AVIVA Biosciences
7.14 Baylor Miraca Genetics Laboratories
7.15 Beckman Coulter Diagnostics
7.16 Becton, Dickinson and Company
7.17 BGI Genomics Co. Ltd
7.18 Bioarray Genetics
7.19 Biocartis
7.20 Biocept, Inc.
7.21 Biodesix Inc.
7.22 BioFluidica
7.23 BioGenex
7.24 BioIVT
7.25 Biolidics Ltd
7.26 bioMerieux Diagnostics
7.27 Bioneer Corporation
7.28 Bio-Rad Laboratories, Inc.
7.29 Bio-Reference Laboratories
7.30 Bio-Techne
7.31 Bioview
7.32 Bolidics
7.33 Boreal Genomics
7.34 Bristol-Myers Squibb
7.35 Burning Rock
7.36 Cancer Genetics
7.37 Caris Molecular Diagnostics
7.38 Castle Biosciences, Inc.
7.39 CellMax Life
7.40 Cepheid (Danaher)
7.41 Charles River Laboratories
7.42 Chronix Biomedical
7.43 Circulogene
7.44 Clinical Genomics
7.45 Cynvenio
7.46 Cytolumina Technologies Corp.
7.47 CytoTrack
7.48 Datar Cancer Genetics Limited
7.49 Diagnologix LLC
7.50 Diasorin S.p.A.
7.51 Enzo Biochem
7.52 Epic Sciences
7.53 Epigenomics AG
7.54 Eurofins Scientific
7.55 Exosome Diagnostics
7.56 Exosome Sciences
7.57 Fabric Genomics
7.58 Fluidigm Corp
7.59 Fluxion Biosciences
7.60 Foundation Medicine
7.61 Freenome
7.62 FUJIFILM Wako Diagnostics
7.63 GeneFirst Ltd.
7.64 Genetron Holdings
7.65 GenomOncology
7.66 GILUPI Nanomedizin
7.67 Grail, Inc.
7.68 Guardant Health
7.69 HalioDx
7.70 HansaBiomed
7.71 HeiScreen
7.72 Helomics
7.73 Horizon Discovery
7.74 HTG Molecular Diagnostics
7.75 iCellate
7.76 Illumina
7.77 Incell Dx
7.78 Inivata
7.79 Integrated Diagnostics
7.80 Invitae Corporation
7.81 Invivogen
7.82 Invivoscribe
7.83 Janssen Diagnostics
7.84 MDNA Life SCIENCES, Inc.
7.85 MDx Health
7.86 Menarini Silicon Biosystems
7.87 Millipore Sigma
7.88 Miltenyi Biotec
7.89 MIODx
7.90 miR Scientific
7.91 Molecular MD
7.92 MyCartis
7.93 Myriad Genetics/Myriad RBM
7.94 NantHealth, Inc.
7.95 Natera
7.96 NeoGenomics
7.97 New Oncology
7.98 NGeneBio
7.99 Novogene Bioinformatics Technology Co., Ltd.
7.100 Oncocyte
7.101 OncoDNA
7.102 Ortho Clinical Diagnostics
7.103 Oxford Nanopore Technologies
7.104 Panagene
7.105 Perkin Elmer
7.106 Personal Genome Diagnostics
7.107 Personalis
7.108 Precipio
7.109 PrecisionMed
7.110 Promega
7.111 Qiagen Gmbh
7.112 Rarecells SAS
7.113 RareCyte
7.114 Roche Molecular Diagnostics
7.115 Screencell
7.116 Sense Biodetection
7.117 Serametrix
7.118 Siemens Healthineers
7.119 Silicon Biosystems
7.120 simfo GmbH
7.121 Singlera Genomics Inc.
7.122 Singulomics
7.123 SkylineDx
7.124 Stratos Genomics
7.125 Sysmex Inostics
7.126 Tempus Labs, Inc.
7.127 Thermo Fisher Scientific Inc.
7.128 Thrive Earlier Detection
7.129 Todos Medical
7.130 Trovagene
7.131 Volition
7.132 Vortex Biosciences

8 The Global Market for Immuno-Oncology Diagnostics
8.1 Global Market Overview by Country
8.2 Global Market by Assay Type - Overview

9 Global Immuno-Oncology Diagnostic Markets - By Assay Type
9.1 Checkpoint
9.2 Cytokine
9.3 Germline Genetic
9.4 Genetic Tumor
9.5 Tumor Microenvironment

10 Appendices
10.1 FDA Cancer Drug Approvals by Year
10.2 Clinical Trials Started 2010 to 2016
10.3 Prevalence of Cancer Treatments
10.4 United States Medicare System: 2021 Clinical Laboratory Fees Schedule

For more information about this report visit https://www.researchandmarkets.com/r/mbm323

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/global-immuno-oncology-diagnostics-market-report-2023-2028-diagnostic-companies-and-instrumentation-suppliers-are-jockeying-for-position-in-a-new-approach-to-conquering-cancer-301725586.html

SOURCE Research and Markets

FAQ

What is the growth forecast for the immuno-oncology diagnostics market according to the 2023 report?

The report anticipates significant growth in the immuno-oncology diagnostics market due to advancements in technology and diagnostics.

What key factors are driving the immuno-oncology diagnostics market?

Factors include the integration of histology, genomics, and liquid biopsy technologies, along with the increasing importance of biomarkers.

What market challenges are highlighted in the 2023 immuno-oncology diagnostics report?

Challenges include the rapid pace of technology development potentially outpacing market readiness and complexities in clinical trial protocols.

Who are the main players in the immuno-oncology diagnostics market?

The market includes various diagnostic companies, pharmaceutical firms, and instrumentation suppliers vying for competitive positioning.

What does the report suggest about the future of immunotherapy in cancer treatment?

The report indicates a revolutionary shift towards using the immune system in cancer therapy, emphasizing the need for effective diagnostics.